A Phase 3 interventional study of Adapalene/Benzoyl Peroxide and Adapalene Gel, 0.1% in Acne Vulgaris, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.
Among the 30 studies testing adapalene in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 2nd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 9 · Phase 4 11
First in 2004; this study’s year is marked. 2 started in 2006.
This study's enrollment of 1,668 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 215 across the 30 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 2nd largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2006, is one of 20 in phase 3, and was the 1st registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing adapalene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations were performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a participant should remain the same during the study.
The primary objective was to demonstrate the superiority in efficacy and assess safety of adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene topical gel, 0.1% (adapalene monad); benzoyl peroxide topical gel, 2.5% (benzoyl peroxide monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12 weeks.
Inclusion Criteria:
Participants were treated with adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
Drug: Adapalene/Benzoyl Peroxide
Participants were treated with 0.1% of adapalene gel topically daily in the evening for 12 Weeks.
Drug: Adapalene Gel, 0.1%
Participants were treated with 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
Drug: Benzoyl Peroxide Gel 2.5%
Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
Drug: Gel Vehicle
Drug pages: Adapalene · Benzoyl Peroxide
Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
0.1% of adapalene gel topically daily in the evening for 12 Weeks.
2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)
Success rate was defined as percentage of participants who achieved "Clear" or "Almost Clear" score on the IGA scale. IGA scale consisted of 5 grades (0-4) among which 0 = Clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting), 1 = Almost clear (Trace, faint pink erythema with almost no induration/papulation and no oozing/crusting), 2 = Mild (Faint pink erythema with mild induration/papulation and no oozing/crusting), 3 = Moderate (Pink-red erythema with moderate induration/papulation and there may be some oozing/crusting.), 4 = Severe (Deep/bright red erythema with severe induration/papulation with oozing/crusting). All missing values were imputed by LOCF.
Time frame: At Week 12
Change in Inflammatory Lesion Count From Baseline to Week 12
Change in inflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Change in Noninflammatory Lesion Count From Baseline to Week 12
Change in noninflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.
Time frame: Baseline to Week 12
Percent Change From Baseline in Inflammatory Lesion Counts at Week 12
The Inflammatory Lesion Count was the sum of papules and pustules. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
Time frame: Baseline, Week 12
Percent Change From Baseline in Noninflammatory Lesion Counts at Week 12
The Noninflammatory Lesion Count was the sum of open comedones and closed comedones. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
Time frame: Baseline, Week 12
Percent Change From Baseline in Total Lesion Counts at Week 12
The Total Lesion Count was the sum of Inflammatory, Noninflammatory Lesion Counts, Nodules and Cysts.
Time frame: Baseline, Week 12
| Milestone | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| Started | 415 | 420 | 415 | 418 |
| Completed | 347 | 363 | 372 | 347 |
| Not completed | 68 | 57 | 43 | 71 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 | 1 |
| Withdrew: Adverse event | 11 | 4 | 5 | 2 |
| Withdrew: Subject request | 21 | 17 | 18 | 30 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 31 | 32 | 19 | 34 |
| Withdrew: Other | 1 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 3 | 1 | 1 | 2 |
Success rate was defined as percentage of participants who achieved "Clear" or "Almost Clear" score on the IGA scale. IGA scale consisted of 5 grades (0-4) among which 0 = Clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting), 1 = Almost clear (Trace, faint pink erythema with almost no induration/papulation and no oozing/crusting), 2 = Mild (Faint pink erythema with mild induration/papulation and no oozing/crusting), 3 = Moderate (Pink-red erythema with moderate induration/papulation and there may be some oozing/crusting.), 4 = Severe (Deep/bright red erythema with severe induration/papulation with oozing/crusting). All missing values were imputed by LOCF.
| percentage of participants | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward) | 30.1 | 19.8 | 22.2 | 11.3 |
Change in inflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.
| lesions | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| Baseline | 27.0 (23 to 35) | 27.0 (23 to 34) | 27.0 (23 to 34) | 27.0 (22 to 35) |
| Change at Week 12 | -16.0 (-22 to -10) | -14.0 (-20 to -7) | -16.0 (-21 to -7) | -10.0 (-16 to -2) |
Change in noninflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.
| lesions | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| Baseline | 44.0 (36 to 62) | 47.0 (37 to 61) | 46.0 (36 to 63) | 46.0 (36 to 62) |
| Change at Week 12 | -24.0 (-35 to -13) | -22.0 (-34 to -11) | -20.0 (-32 to -7) | -14.0 (-25 to -1) |
The Inflammatory Lesion Count was the sum of papules and pustules. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
| percent change | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| Percent Change From Baseline in Inflammatory Lesion Counts at Week 12 | -55.33 ± 34.678 | -41.68 ± 41.855 | -47.61 ± 38.415 | -30.23 ± 41.661 |
The Noninflammatory Lesion Count was the sum of open comedones and closed comedones. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
| percent change | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| Percent Change From Baseline in Noninflammatory Lesion Counts at Week 12 | -48.15 ± 35.428 | -40.75 ± 40.822 | -37.23 ± 39.758 | -23.22 ± 48.613 |
The Total Lesion Count was the sum of Inflammatory, Noninflammatory Lesion Counts, Nodules and Cysts.
| percent change in lesions | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| Percent Change From Baseline in Total Lesion Counts at Week 12 | -49.97 ± 31.966 | -41.29 ± 36.133 | -41.23 ± 33.794 | -26.06 ± 38.714 |
Collected over From start of the study drug administration up to Week 12.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adapalene/Benzoyl Peroxide Gel | 0/415 (0%) | 2/415 (0.5%) | 44/415 (10.6%) |
| Adapalene Gel, 0.1% | 0/420 (0%) | 3/420 (0.7%) | 51/420 (12.1%) |
| Benzoyl Peroxide Gel 2.5% | 0/415 (0%) | 0/415 (0%) | 29/415 (7%) |
| Gel Vehicle | 0/418 (0%) | 1/418 (0.2%) | 34/418 (8.1%) |
| Event | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 1/415 | 1/420 | 0/415 | 0/418 |
| Suicide attemptPsychiatric disorders | 1/415 | 0/420 | 0/415 | 0/418 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/415 | 0/420 | 0/415 | 1/418 |
| Affective disorderPsychiatric disorders | 0/415 | 1/420 | 0/415 | 0/418 |
| AbscessInfections and infestations | 0/415 | 1/420 | 0/415 | 0/418 |
| Cellulitis staphylococcalInfections and infestations | 0/415 | 1/420 | 0/415 | 0/418 |
| Event | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 16/415 | 30/420 | 20/415 | 21/418 |
| Dry skinSkin and subcutaneous tissue disorders | 28/415 | 21/420 | 9/415 | 13/418 |
ITT (Intent-to-Treat) Population included all treated participants.
| Age, Continuous(years) | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle | Total |
|---|---|---|---|---|---|
| Mean | 18.7 ± 7.14 | 17.9 ± 5.40 | 18.4 ± 6.55 | 18.0 ± 6.09 | 18.2 ± 6.33 |
| Sex: Female, Male(Participants) | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle | Total |
|---|---|---|---|---|---|
| Female | 210 | 217 | 207 | 222 | 856 |
| Male | 205 | 203 | 208 | 196 | 812 |
| Race/Ethnicity, Customized(Participants) | Adapalene/Benzoyl Peroxide Gel | Adapalene Gel, 0.1% | Benzoyl Peroxide Gel 2.5% | Gel Vehicle | Total |
|---|---|---|---|---|---|
| Caucasian | 273 | 281 | 258 | 270 | 1082 |
| Black | 66 | 64 | 81 | 66 | 277 |
| Asian | 4 | 4 | 4 | 5 | 17 |
| Hispanic | 67 | 66 | 65 | 72 | 270 |
| Other | 5 | 5 | 7 | 5 | 22 |
Ran from Jun 2006 to primary completion in Jul 2007, 12 months.
Results were first posted in Apr 2024, 16 years 9 months after primary completion.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 12 months is close to that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adapalene · Benzoyl Peroxide